Global Antihemophilic Factor Drug Market Growth 2025-2031
The global Antihemophilic Factor Drug market size is predicted to grow from US$ 607 million in 2025 to US$ 878 million in 2031; it is expected to grow at a CAGR of 6.3% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Antihemophilic Factor Drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Antihemophilic Factor Drug Industry Forecast? looks at past sales and reviews total world Antihemophilic Factor Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Antihemophilic Factor Drug sales for 2025 through 2031. With Antihemophilic Factor Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antihemophilic Factor Drug industry.
This Insight Report provides a comprehensive analysis of the global Antihemophilic Factor Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antihemophilic Factor Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Antihemophilic Factor Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antihemophilic Factor Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antihemophilic Factor Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Antihemophilic Factor Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Antihemophilic Factor Drug market?
What factors are driving Antihemophilic Factor Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antihemophilic Factor Drug market opportunities vary by end market size?
How does Antihemophilic Factor Drug break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Antihemophilic Factor Drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Antihemophilic Factor Drug Industry Forecast? looks at past sales and reviews total world Antihemophilic Factor Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Antihemophilic Factor Drug sales for 2025 through 2031. With Antihemophilic Factor Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antihemophilic Factor Drug industry.
This Insight Report provides a comprehensive analysis of the global Antihemophilic Factor Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antihemophilic Factor Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Antihemophilic Factor Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antihemophilic Factor Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antihemophilic Factor Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Antihemophilic Factor Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 250 IU
- 500 IU
- 1000 IU
- 1500 IU
- 2000 IU
- 3000 IU
- 4000 IU
- Other potencies
- Adult
- Pediatric
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bayer
- Takeda
- Novo Nordisk
- Pfizer
- Grifols
- CSL Behring
- Sanofi
- Cigna
- Octapharma
- GC Pharma
- Hualan Biological Engineering
- Shanghai RAAS blood products
What is the 10-year outlook for the global Antihemophilic Factor Drug market?
What factors are driving Antihemophilic Factor Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antihemophilic Factor Drug market opportunities vary by end market size?
How does Antihemophilic Factor Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antihemophilic Factor Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Antihemophilic Factor Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Antihemophilic Factor Drug by Country/Region, 2020, 2024 & 2031
2.2 Antihemophilic Factor Drug Segment by Type
2.2.1 250 IU
2.2.2 500 IU
2.2.3 1000 IU
2.2.4 1500 IU
2.2.5 2000 IU
2.2.6 3000 IU
2.2.7 4000 IU
2.2.8 Other potencies
2.3 Antihemophilic Factor Drug Sales by Type
2.3.1 Global Antihemophilic Factor Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Antihemophilic Factor Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Antihemophilic Factor Drug Sale Price by Type (2020-2025)
2.4 Antihemophilic Factor Drug Segment by Application
2.4.1 Adult
2.4.2 Pediatric
2.5 Antihemophilic Factor Drug Sales by Application
2.5.1 Global Antihemophilic Factor Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Antihemophilic Factor Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Antihemophilic Factor Drug Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Antihemophilic Factor Drug Breakdown Data by Company
3.1.1 Global Antihemophilic Factor Drug Annual Sales by Company (2020-2025)
3.1.2 Global Antihemophilic Factor Drug Sales Market Share by Company (2020-2025)
3.2 Global Antihemophilic Factor Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Antihemophilic Factor Drug Revenue by Company (2020-2025)
3.2.2 Global Antihemophilic Factor Drug Revenue Market Share by Company (2020-2025)
3.3 Global Antihemophilic Factor Drug Sale Price by Company
3.4 Key Manufacturers Antihemophilic Factor Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Antihemophilic Factor Drug Product Location Distribution
3.4.2 Players Antihemophilic Factor Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTIHEMOPHILIC FACTOR DRUG BY GEOGRAPHIC REGION
4.1 World Historic Antihemophilic Factor Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Antihemophilic Factor Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Antihemophilic Factor Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Antihemophilic Factor Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Antihemophilic Factor Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Antihemophilic Factor Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Antihemophilic Factor Drug Sales Growth
4.4 APAC Antihemophilic Factor Drug Sales Growth
4.5 Europe Antihemophilic Factor Drug Sales Growth
4.6 Middle East & Africa Antihemophilic Factor Drug Sales Growth
5 AMERICAS
5.1 Americas Antihemophilic Factor Drug Sales by Country
5.1.1 Americas Antihemophilic Factor Drug Sales by Country (2020-2025)
5.1.2 Americas Antihemophilic Factor Drug Revenue by Country (2020-2025)
5.2 Americas Antihemophilic Factor Drug Sales by Type (2020-2025)
5.3 Americas Antihemophilic Factor Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antihemophilic Factor Drug Sales by Region
6.1.1 APAC Antihemophilic Factor Drug Sales by Region (2020-2025)
6.1.2 APAC Antihemophilic Factor Drug Revenue by Region (2020-2025)
6.2 APAC Antihemophilic Factor Drug Sales by Type (2020-2025)
6.3 APAC Antihemophilic Factor Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Antihemophilic Factor Drug by Country
7.1.1 Europe Antihemophilic Factor Drug Sales by Country (2020-2025)
7.1.2 Europe Antihemophilic Factor Drug Revenue by Country (2020-2025)
7.2 Europe Antihemophilic Factor Drug Sales by Type (2020-2025)
7.3 Europe Antihemophilic Factor Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antihemophilic Factor Drug by Country
8.1.1 Middle East & Africa Antihemophilic Factor Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Antihemophilic Factor Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Antihemophilic Factor Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Antihemophilic Factor Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antihemophilic Factor Drug
10.3 Manufacturing Process Analysis of Antihemophilic Factor Drug
10.4 Industry Chain Structure of Antihemophilic Factor Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Antihemophilic Factor Drug Distributors
11.3 Antihemophilic Factor Drug Customer
12 WORLD FORECAST REVIEW FOR ANTIHEMOPHILIC FACTOR DRUG BY GEOGRAPHIC REGION
12.1 Global Antihemophilic Factor Drug Market Size Forecast by Region
12.1.1 Global Antihemophilic Factor Drug Forecast by Region (2026-2031)
12.1.2 Global Antihemophilic Factor Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Antihemophilic Factor Drug Forecast by Type (2026-2031)
12.7 Global Antihemophilic Factor Drug Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Bayer
13.1.1 Bayer Company Information
13.1.2 Bayer Antihemophilic Factor Drug Product Portfolios and Specifications
13.1.3 Bayer Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Bayer Main Business Overview
13.1.5 Bayer Latest Developments
13.2 Takeda
13.2.1 Takeda Company Information
13.2.2 Takeda Antihemophilic Factor Drug Product Portfolios and Specifications
13.2.3 Takeda Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Takeda Main Business Overview
13.2.5 Takeda Latest Developments
13.3 Novo Nordisk
13.3.1 Novo Nordisk Company Information
13.3.2 Novo Nordisk Antihemophilic Factor Drug Product Portfolios and Specifications
13.3.3 Novo Nordisk Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Novo Nordisk Main Business Overview
13.3.5 Novo Nordisk Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Antihemophilic Factor Drug Product Portfolios and Specifications
13.4.3 Pfizer Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Grifols
13.5.1 Grifols Company Information
13.5.2 Grifols Antihemophilic Factor Drug Product Portfolios and Specifications
13.5.3 Grifols Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Grifols Main Business Overview
13.5.5 Grifols Latest Developments
13.6 CSL Behring
13.6.1 CSL Behring Company Information
13.6.2 CSL Behring Antihemophilic Factor Drug Product Portfolios and Specifications
13.6.3 CSL Behring Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 CSL Behring Main Business Overview
13.6.5 CSL Behring Latest Developments
13.7 Sanofi
13.7.1 Sanofi Company Information
13.7.2 Sanofi Antihemophilic Factor Drug Product Portfolios and Specifications
13.7.3 Sanofi Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Sanofi Main Business Overview
13.7.5 Sanofi Latest Developments
13.8 Cigna
13.8.1 Cigna Company Information
13.8.2 Cigna Antihemophilic Factor Drug Product Portfolios and Specifications
13.8.3 Cigna Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Cigna Main Business Overview
13.8.5 Cigna Latest Developments
13.9 Octapharma
13.9.1 Octapharma Company Information
13.9.2 Octapharma Antihemophilic Factor Drug Product Portfolios and Specifications
13.9.3 Octapharma Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Octapharma Main Business Overview
13.9.5 Octapharma Latest Developments
13.10 GC Pharma
13.10.1 GC Pharma Company Information
13.10.2 GC Pharma Antihemophilic Factor Drug Product Portfolios and Specifications
13.10.3 GC Pharma Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 GC Pharma Main Business Overview
13.10.5 GC Pharma Latest Developments
13.11 Hualan Biological Engineering
13.11.1 Hualan Biological Engineering Company Information
13.11.2 Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolios and Specifications
13.11.3 Hualan Biological Engineering Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Hualan Biological Engineering Main Business Overview
13.11.5 Hualan Biological Engineering Latest Developments
13.12 Shanghai RAAS blood products
13.12.1 Shanghai RAAS blood products Company Information
13.12.2 Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolios and Specifications
13.12.3 Shanghai RAAS blood products Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Shanghai RAAS blood products Main Business Overview
13.12.5 Shanghai RAAS blood products Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antihemophilic Factor Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Antihemophilic Factor Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Antihemophilic Factor Drug by Country/Region, 2020, 2024 & 2031
2.2 Antihemophilic Factor Drug Segment by Type
2.2.1 250 IU
2.2.2 500 IU
2.2.3 1000 IU
2.2.4 1500 IU
2.2.5 2000 IU
2.2.6 3000 IU
2.2.7 4000 IU
2.2.8 Other potencies
2.3 Antihemophilic Factor Drug Sales by Type
2.3.1 Global Antihemophilic Factor Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Antihemophilic Factor Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Antihemophilic Factor Drug Sale Price by Type (2020-2025)
2.4 Antihemophilic Factor Drug Segment by Application
2.4.1 Adult
2.4.2 Pediatric
2.5 Antihemophilic Factor Drug Sales by Application
2.5.1 Global Antihemophilic Factor Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Antihemophilic Factor Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Antihemophilic Factor Drug Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Antihemophilic Factor Drug Breakdown Data by Company
3.1.1 Global Antihemophilic Factor Drug Annual Sales by Company (2020-2025)
3.1.2 Global Antihemophilic Factor Drug Sales Market Share by Company (2020-2025)
3.2 Global Antihemophilic Factor Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Antihemophilic Factor Drug Revenue by Company (2020-2025)
3.2.2 Global Antihemophilic Factor Drug Revenue Market Share by Company (2020-2025)
3.3 Global Antihemophilic Factor Drug Sale Price by Company
3.4 Key Manufacturers Antihemophilic Factor Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Antihemophilic Factor Drug Product Location Distribution
3.4.2 Players Antihemophilic Factor Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTIHEMOPHILIC FACTOR DRUG BY GEOGRAPHIC REGION
4.1 World Historic Antihemophilic Factor Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Antihemophilic Factor Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Antihemophilic Factor Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Antihemophilic Factor Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Antihemophilic Factor Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Antihemophilic Factor Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Antihemophilic Factor Drug Sales Growth
4.4 APAC Antihemophilic Factor Drug Sales Growth
4.5 Europe Antihemophilic Factor Drug Sales Growth
4.6 Middle East & Africa Antihemophilic Factor Drug Sales Growth
5 AMERICAS
5.1 Americas Antihemophilic Factor Drug Sales by Country
5.1.1 Americas Antihemophilic Factor Drug Sales by Country (2020-2025)
5.1.2 Americas Antihemophilic Factor Drug Revenue by Country (2020-2025)
5.2 Americas Antihemophilic Factor Drug Sales by Type (2020-2025)
5.3 Americas Antihemophilic Factor Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antihemophilic Factor Drug Sales by Region
6.1.1 APAC Antihemophilic Factor Drug Sales by Region (2020-2025)
6.1.2 APAC Antihemophilic Factor Drug Revenue by Region (2020-2025)
6.2 APAC Antihemophilic Factor Drug Sales by Type (2020-2025)
6.3 APAC Antihemophilic Factor Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Antihemophilic Factor Drug by Country
7.1.1 Europe Antihemophilic Factor Drug Sales by Country (2020-2025)
7.1.2 Europe Antihemophilic Factor Drug Revenue by Country (2020-2025)
7.2 Europe Antihemophilic Factor Drug Sales by Type (2020-2025)
7.3 Europe Antihemophilic Factor Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antihemophilic Factor Drug by Country
8.1.1 Middle East & Africa Antihemophilic Factor Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Antihemophilic Factor Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Antihemophilic Factor Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Antihemophilic Factor Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antihemophilic Factor Drug
10.3 Manufacturing Process Analysis of Antihemophilic Factor Drug
10.4 Industry Chain Structure of Antihemophilic Factor Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Antihemophilic Factor Drug Distributors
11.3 Antihemophilic Factor Drug Customer
12 WORLD FORECAST REVIEW FOR ANTIHEMOPHILIC FACTOR DRUG BY GEOGRAPHIC REGION
12.1 Global Antihemophilic Factor Drug Market Size Forecast by Region
12.1.1 Global Antihemophilic Factor Drug Forecast by Region (2026-2031)
12.1.2 Global Antihemophilic Factor Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Antihemophilic Factor Drug Forecast by Type (2026-2031)
12.7 Global Antihemophilic Factor Drug Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Bayer
13.1.1 Bayer Company Information
13.1.2 Bayer Antihemophilic Factor Drug Product Portfolios and Specifications
13.1.3 Bayer Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Bayer Main Business Overview
13.1.5 Bayer Latest Developments
13.2 Takeda
13.2.1 Takeda Company Information
13.2.2 Takeda Antihemophilic Factor Drug Product Portfolios and Specifications
13.2.3 Takeda Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Takeda Main Business Overview
13.2.5 Takeda Latest Developments
13.3 Novo Nordisk
13.3.1 Novo Nordisk Company Information
13.3.2 Novo Nordisk Antihemophilic Factor Drug Product Portfolios and Specifications
13.3.3 Novo Nordisk Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Novo Nordisk Main Business Overview
13.3.5 Novo Nordisk Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Antihemophilic Factor Drug Product Portfolios and Specifications
13.4.3 Pfizer Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Grifols
13.5.1 Grifols Company Information
13.5.2 Grifols Antihemophilic Factor Drug Product Portfolios and Specifications
13.5.3 Grifols Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Grifols Main Business Overview
13.5.5 Grifols Latest Developments
13.6 CSL Behring
13.6.1 CSL Behring Company Information
13.6.2 CSL Behring Antihemophilic Factor Drug Product Portfolios and Specifications
13.6.3 CSL Behring Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 CSL Behring Main Business Overview
13.6.5 CSL Behring Latest Developments
13.7 Sanofi
13.7.1 Sanofi Company Information
13.7.2 Sanofi Antihemophilic Factor Drug Product Portfolios and Specifications
13.7.3 Sanofi Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Sanofi Main Business Overview
13.7.5 Sanofi Latest Developments
13.8 Cigna
13.8.1 Cigna Company Information
13.8.2 Cigna Antihemophilic Factor Drug Product Portfolios and Specifications
13.8.3 Cigna Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Cigna Main Business Overview
13.8.5 Cigna Latest Developments
13.9 Octapharma
13.9.1 Octapharma Company Information
13.9.2 Octapharma Antihemophilic Factor Drug Product Portfolios and Specifications
13.9.3 Octapharma Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Octapharma Main Business Overview
13.9.5 Octapharma Latest Developments
13.10 GC Pharma
13.10.1 GC Pharma Company Information
13.10.2 GC Pharma Antihemophilic Factor Drug Product Portfolios and Specifications
13.10.3 GC Pharma Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 GC Pharma Main Business Overview
13.10.5 GC Pharma Latest Developments
13.11 Hualan Biological Engineering
13.11.1 Hualan Biological Engineering Company Information
13.11.2 Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolios and Specifications
13.11.3 Hualan Biological Engineering Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Hualan Biological Engineering Main Business Overview
13.11.5 Hualan Biological Engineering Latest Developments
13.12 Shanghai RAAS blood products
13.12.1 Shanghai RAAS blood products Company Information
13.12.2 Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolios and Specifications
13.12.3 Shanghai RAAS blood products Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Shanghai RAAS blood products Main Business Overview
13.12.5 Shanghai RAAS blood products Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Antihemophilic Factor Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Antihemophilic Factor Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of 250 IU
Table 4. Major Players of 500 IU
Table 5. Major Players of 1000 IU
Table 6. Major Players of 1500 IU
Table 7. Major Players of 2000 IU
Table 8. Major Players of 3000 IU
Table 9. Major Players of 4000 IU
Table 10. Major Players of Other potencies
Table 11. Global Antihemophilic Factor Drug Sales by Type (2020-2025) & (K Units)
Table 12. Global Antihemophilic Factor Drug Sales Market Share by Type (2020-2025)
Table 13. Global Antihemophilic Factor Drug Revenue by Type (2020-2025) & ($ million)
Table 14. Global Antihemophilic Factor Drug Revenue Market Share by Type (2020-2025)
Table 15. Global Antihemophilic Factor Drug Sale Price by Type (2020-2025) & (USD/Unit)
Table 16. Global Antihemophilic Factor Drug Sale by Application (2020-2025) & (K Units)
Table 17. Global Antihemophilic Factor Drug Sale Market Share by Application (2020-2025)
Table 18. Global Antihemophilic Factor Drug Revenue by Application (2020-2025) & ($ million)
Table 19. Global Antihemophilic Factor Drug Revenue Market Share by Application (2020-2025)
Table 20. Global Antihemophilic Factor Drug Sale Price by Application (2020-2025) & (USD/Unit)
Table 21. Global Antihemophilic Factor Drug Sales by Company (2020-2025) & (K Units)
Table 22. Global Antihemophilic Factor Drug Sales Market Share by Company (2020-2025)
Table 23. Global Antihemophilic Factor Drug Revenue by Company (2020-2025) & ($ millions)
Table 24. Global Antihemophilic Factor Drug Revenue Market Share by Company (2020-2025)
Table 25. Global Antihemophilic Factor Drug Sale Price by Company (2020-2025) & (USD/Unit)
Table 26. Key Manufacturers Antihemophilic Factor Drug Producing Area Distribution and Sales Area
Table 27. Players Antihemophilic Factor Drug Products Offered
Table 28. Antihemophilic Factor Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 29. New Products and Potential Entrants
Table 30. Market M&A Activity & Strategy
Table 31. Global Antihemophilic Factor Drug Sales by Geographic Region (2020-2025) & (K Units)
Table 32. Global Antihemophilic Factor Drug Sales Market Share Geographic Region (2020-2025)
Table 33. Global Antihemophilic Factor Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 34. Global Antihemophilic Factor Drug Revenue Market Share by Geographic Region (2020-2025)
Table 35. Global Antihemophilic Factor Drug Sales by Country/Region (2020-2025) & (K Units)
Table 36. Global Antihemophilic Factor Drug Sales Market Share by Country/Region (2020-2025)
Table 37. Global Antihemophilic Factor Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 38. Global Antihemophilic Factor Drug Revenue Market Share by Country/Region (2020-2025)
Table 39. Americas Antihemophilic Factor Drug Sales by Country (2020-2025) & (K Units)
Table 40. Americas Antihemophilic Factor Drug Sales Market Share by Country (2020-2025)
Table 41. Americas Antihemophilic Factor Drug Revenue by Country (2020-2025) & ($ millions)
Table 42. Americas Antihemophilic Factor Drug Sales by Type (2020-2025) & (K Units)
Table 43. Americas Antihemophilic Factor Drug Sales by Application (2020-2025) & (K Units)
Table 44. APAC Antihemophilic Factor Drug Sales by Region (2020-2025) & (K Units)
Table 45. APAC Antihemophilic Factor Drug Sales Market Share by Region (2020-2025)
Table 46. APAC Antihemophilic Factor Drug Revenue by Region (2020-2025) & ($ millions)
Table 47. APAC Antihemophilic Factor Drug Sales by Type (2020-2025) & (K Units)
Table 48. APAC Antihemophilic Factor Drug Sales by Application (2020-2025) & (K Units)
Table 49. Europe Antihemophilic Factor Drug Sales by Country (2020-2025) & (K Units)
Table 50. Europe Antihemophilic Factor Drug Revenue by Country (2020-2025) & ($ millions)
Table 51. Europe Antihemophilic Factor Drug Sales by Type (2020-2025) & (K Units)
Table 52. Europe Antihemophilic Factor Drug Sales by Application (2020-2025) & (K Units)
Table 53. Middle East & Africa Antihemophilic Factor Drug Sales by Country (2020-2025) & (K Units)
Table 54. Middle East & Africa Antihemophilic Factor Drug Revenue Market Share by Country (2020-2025)
Table 55. Middle East & Africa Antihemophilic Factor Drug Sales by Type (2020-2025) & (K Units)
Table 56. Middle East & Africa Antihemophilic Factor Drug Sales by Application (2020-2025) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Antihemophilic Factor Drug
Table 58. Key Market Challenges & Risks of Antihemophilic Factor Drug
Table 59. Key Industry Trends of Antihemophilic Factor Drug
Table 60. Antihemophilic Factor Drug Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Antihemophilic Factor Drug Distributors List
Table 63. Antihemophilic Factor Drug Customer List
Table 64. Global Antihemophilic Factor Drug Sales Forecast by Region (2026-2031) & (K Units)
Table 65. Global Antihemophilic Factor Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 66. Americas Antihemophilic Factor Drug Sales Forecast by Country (2026-2031) & (K Units)
Table 67. Americas Antihemophilic Factor Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. APAC Antihemophilic Factor Drug Sales Forecast by Region (2026-2031) & (K Units)
Table 69. APAC Antihemophilic Factor Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 70. Europe Antihemophilic Factor Drug Sales Forecast by Country (2026-2031) & (K Units)
Table 71. Europe Antihemophilic Factor Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 72. Middle East & Africa Antihemophilic Factor Drug Sales Forecast by Country (2026-2031) & (K Units)
Table 73. Middle East & Africa Antihemophilic Factor Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 74. Global Antihemophilic Factor Drug Sales Forecast by Type (2026-2031) & (K Units)
Table 75. Global Antihemophilic Factor Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 76. Global Antihemophilic Factor Drug Sales Forecast by Application (2026-2031) & (K Units)
Table 77. Global Antihemophilic Factor Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 78. Bayer Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 79. Bayer Antihemophilic Factor Drug Product Portfolios and Specifications
Table 80. Bayer Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Bayer Main Business
Table 82. Bayer Latest Developments
Table 83. Takeda Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 84. Takeda Antihemophilic Factor Drug Product Portfolios and Specifications
Table 85. Takeda Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. Takeda Main Business
Table 87. Takeda Latest Developments
Table 88. Novo Nordisk Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 89. Novo Nordisk Antihemophilic Factor Drug Product Portfolios and Specifications
Table 90. Novo Nordisk Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. Novo Nordisk Main Business
Table 92. Novo Nordisk Latest Developments
Table 93. Pfizer Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer Antihemophilic Factor Drug Product Portfolios and Specifications
Table 95. Pfizer Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Pfizer Main Business
Table 97. Pfizer Latest Developments
Table 98. Grifols Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Grifols Antihemophilic Factor Drug Product Portfolios and Specifications
Table 100. Grifols Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 101. Grifols Main Business
Table 102. Grifols Latest Developments
Table 103. CSL Behring Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. CSL Behring Antihemophilic Factor Drug Product Portfolios and Specifications
Table 105. CSL Behring Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 106. CSL Behring Main Business
Table 107. CSL Behring Latest Developments
Table 108. Sanofi Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. Sanofi Antihemophilic Factor Drug Product Portfolios and Specifications
Table 110. Sanofi Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 111. Sanofi Main Business
Table 112. Sanofi Latest Developments
Table 113. Cigna Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 114. Cigna Antihemophilic Factor Drug Product Portfolios and Specifications
Table 115. Cigna Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 116. Cigna Main Business
Table 117. Cigna Latest Developments
Table 118. Octapharma Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 119. Octapharma Antihemophilic Factor Drug Product Portfolios and Specifications
Table 120. Octapharma Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 121. Octapharma Main Business
Table 122. Octapharma Latest Developments
Table 123. GC Pharma Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 124. GC Pharma Antihemophilic Factor Drug Product Portfolios and Specifications
Table 125. GC Pharma Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 126. GC Pharma Main Business
Table 127. GC Pharma Latest Developments
Table 128. Hualan Biological Engineering Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 129. Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolios and Specifications
Table 130. Hualan Biological Engineering Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 131. Hualan Biological Engineering Main Business
Table 132. Hualan Biological Engineering Latest Developments
Table 133. Shanghai RAAS blood products Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 134. Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolios and Specifications
Table 135. Shanghai RAAS blood products Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 136. Shanghai RAAS blood products Main Business
Table 137. Shanghai RAAS blood products Latest Developments
Table 1. Antihemophilic Factor Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Antihemophilic Factor Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of 250 IU
Table 4. Major Players of 500 IU
Table 5. Major Players of 1000 IU
Table 6. Major Players of 1500 IU
Table 7. Major Players of 2000 IU
Table 8. Major Players of 3000 IU
Table 9. Major Players of 4000 IU
Table 10. Major Players of Other potencies
Table 11. Global Antihemophilic Factor Drug Sales by Type (2020-2025) & (K Units)
Table 12. Global Antihemophilic Factor Drug Sales Market Share by Type (2020-2025)
Table 13. Global Antihemophilic Factor Drug Revenue by Type (2020-2025) & ($ million)
Table 14. Global Antihemophilic Factor Drug Revenue Market Share by Type (2020-2025)
Table 15. Global Antihemophilic Factor Drug Sale Price by Type (2020-2025) & (USD/Unit)
Table 16. Global Antihemophilic Factor Drug Sale by Application (2020-2025) & (K Units)
Table 17. Global Antihemophilic Factor Drug Sale Market Share by Application (2020-2025)
Table 18. Global Antihemophilic Factor Drug Revenue by Application (2020-2025) & ($ million)
Table 19. Global Antihemophilic Factor Drug Revenue Market Share by Application (2020-2025)
Table 20. Global Antihemophilic Factor Drug Sale Price by Application (2020-2025) & (USD/Unit)
Table 21. Global Antihemophilic Factor Drug Sales by Company (2020-2025) & (K Units)
Table 22. Global Antihemophilic Factor Drug Sales Market Share by Company (2020-2025)
Table 23. Global Antihemophilic Factor Drug Revenue by Company (2020-2025) & ($ millions)
Table 24. Global Antihemophilic Factor Drug Revenue Market Share by Company (2020-2025)
Table 25. Global Antihemophilic Factor Drug Sale Price by Company (2020-2025) & (USD/Unit)
Table 26. Key Manufacturers Antihemophilic Factor Drug Producing Area Distribution and Sales Area
Table 27. Players Antihemophilic Factor Drug Products Offered
Table 28. Antihemophilic Factor Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 29. New Products and Potential Entrants
Table 30. Market M&A Activity & Strategy
Table 31. Global Antihemophilic Factor Drug Sales by Geographic Region (2020-2025) & (K Units)
Table 32. Global Antihemophilic Factor Drug Sales Market Share Geographic Region (2020-2025)
Table 33. Global Antihemophilic Factor Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 34. Global Antihemophilic Factor Drug Revenue Market Share by Geographic Region (2020-2025)
Table 35. Global Antihemophilic Factor Drug Sales by Country/Region (2020-2025) & (K Units)
Table 36. Global Antihemophilic Factor Drug Sales Market Share by Country/Region (2020-2025)
Table 37. Global Antihemophilic Factor Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 38. Global Antihemophilic Factor Drug Revenue Market Share by Country/Region (2020-2025)
Table 39. Americas Antihemophilic Factor Drug Sales by Country (2020-2025) & (K Units)
Table 40. Americas Antihemophilic Factor Drug Sales Market Share by Country (2020-2025)
Table 41. Americas Antihemophilic Factor Drug Revenue by Country (2020-2025) & ($ millions)
Table 42. Americas Antihemophilic Factor Drug Sales by Type (2020-2025) & (K Units)
Table 43. Americas Antihemophilic Factor Drug Sales by Application (2020-2025) & (K Units)
Table 44. APAC Antihemophilic Factor Drug Sales by Region (2020-2025) & (K Units)
Table 45. APAC Antihemophilic Factor Drug Sales Market Share by Region (2020-2025)
Table 46. APAC Antihemophilic Factor Drug Revenue by Region (2020-2025) & ($ millions)
Table 47. APAC Antihemophilic Factor Drug Sales by Type (2020-2025) & (K Units)
Table 48. APAC Antihemophilic Factor Drug Sales by Application (2020-2025) & (K Units)
Table 49. Europe Antihemophilic Factor Drug Sales by Country (2020-2025) & (K Units)
Table 50. Europe Antihemophilic Factor Drug Revenue by Country (2020-2025) & ($ millions)
Table 51. Europe Antihemophilic Factor Drug Sales by Type (2020-2025) & (K Units)
Table 52. Europe Antihemophilic Factor Drug Sales by Application (2020-2025) & (K Units)
Table 53. Middle East & Africa Antihemophilic Factor Drug Sales by Country (2020-2025) & (K Units)
Table 54. Middle East & Africa Antihemophilic Factor Drug Revenue Market Share by Country (2020-2025)
Table 55. Middle East & Africa Antihemophilic Factor Drug Sales by Type (2020-2025) & (K Units)
Table 56. Middle East & Africa Antihemophilic Factor Drug Sales by Application (2020-2025) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Antihemophilic Factor Drug
Table 58. Key Market Challenges & Risks of Antihemophilic Factor Drug
Table 59. Key Industry Trends of Antihemophilic Factor Drug
Table 60. Antihemophilic Factor Drug Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Antihemophilic Factor Drug Distributors List
Table 63. Antihemophilic Factor Drug Customer List
Table 64. Global Antihemophilic Factor Drug Sales Forecast by Region (2026-2031) & (K Units)
Table 65. Global Antihemophilic Factor Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 66. Americas Antihemophilic Factor Drug Sales Forecast by Country (2026-2031) & (K Units)
Table 67. Americas Antihemophilic Factor Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. APAC Antihemophilic Factor Drug Sales Forecast by Region (2026-2031) & (K Units)
Table 69. APAC Antihemophilic Factor Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 70. Europe Antihemophilic Factor Drug Sales Forecast by Country (2026-2031) & (K Units)
Table 71. Europe Antihemophilic Factor Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 72. Middle East & Africa Antihemophilic Factor Drug Sales Forecast by Country (2026-2031) & (K Units)
Table 73. Middle East & Africa Antihemophilic Factor Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 74. Global Antihemophilic Factor Drug Sales Forecast by Type (2026-2031) & (K Units)
Table 75. Global Antihemophilic Factor Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 76. Global Antihemophilic Factor Drug Sales Forecast by Application (2026-2031) & (K Units)
Table 77. Global Antihemophilic Factor Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 78. Bayer Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 79. Bayer Antihemophilic Factor Drug Product Portfolios and Specifications
Table 80. Bayer Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Bayer Main Business
Table 82. Bayer Latest Developments
Table 83. Takeda Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 84. Takeda Antihemophilic Factor Drug Product Portfolios and Specifications
Table 85. Takeda Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. Takeda Main Business
Table 87. Takeda Latest Developments
Table 88. Novo Nordisk Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 89. Novo Nordisk Antihemophilic Factor Drug Product Portfolios and Specifications
Table 90. Novo Nordisk Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. Novo Nordisk Main Business
Table 92. Novo Nordisk Latest Developments
Table 93. Pfizer Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer Antihemophilic Factor Drug Product Portfolios and Specifications
Table 95. Pfizer Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Pfizer Main Business
Table 97. Pfizer Latest Developments
Table 98. Grifols Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Grifols Antihemophilic Factor Drug Product Portfolios and Specifications
Table 100. Grifols Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 101. Grifols Main Business
Table 102. Grifols Latest Developments
Table 103. CSL Behring Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. CSL Behring Antihemophilic Factor Drug Product Portfolios and Specifications
Table 105. CSL Behring Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 106. CSL Behring Main Business
Table 107. CSL Behring Latest Developments
Table 108. Sanofi Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. Sanofi Antihemophilic Factor Drug Product Portfolios and Specifications
Table 110. Sanofi Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 111. Sanofi Main Business
Table 112. Sanofi Latest Developments
Table 113. Cigna Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 114. Cigna Antihemophilic Factor Drug Product Portfolios and Specifications
Table 115. Cigna Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 116. Cigna Main Business
Table 117. Cigna Latest Developments
Table 118. Octapharma Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 119. Octapharma Antihemophilic Factor Drug Product Portfolios and Specifications
Table 120. Octapharma Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 121. Octapharma Main Business
Table 122. Octapharma Latest Developments
Table 123. GC Pharma Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 124. GC Pharma Antihemophilic Factor Drug Product Portfolios and Specifications
Table 125. GC Pharma Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 126. GC Pharma Main Business
Table 127. GC Pharma Latest Developments
Table 128. Hualan Biological Engineering Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 129. Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolios and Specifications
Table 130. Hualan Biological Engineering Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 131. Hualan Biological Engineering Main Business
Table 132. Hualan Biological Engineering Latest Developments
Table 133. Shanghai RAAS blood products Basic Information, Antihemophilic Factor Drug Manufacturing Base, Sales Area and Its Competitors
Table 134. Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolios and Specifications
Table 135. Shanghai RAAS blood products Antihemophilic Factor Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 136. Shanghai RAAS blood products Main Business
Table 137. Shanghai RAAS blood products Latest Developments
LIST OF FIGURES
Figure 1. Picture of Antihemophilic Factor Drug
Figure 2. Antihemophilic Factor Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Antihemophilic Factor Drug Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Antihemophilic Factor Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Antihemophilic Factor Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Antihemophilic Factor Drug Sales Market Share by Country/Region (2024)
Figure 10. Antihemophilic Factor Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of 250 IU
Figure 12. Product Picture of 500 IU
Figure 13. Product Picture of 1000 IU
Figure 14. Product Picture of 1500 IU
Figure 15. Product Picture of 2000 IU
Figure 16. Product Picture of 3000 IU
Figure 17. Product Picture of 4000 IU
Figure 18. Product Picture of Other potencies
Figure 19. Global Antihemophilic Factor Drug Sales Market Share by Type in 2025
Figure 20. Global Antihemophilic Factor Drug Revenue Market Share by Type (2020-2025)
Figure 21. Antihemophilic Factor Drug Consumed in Adult
Figure 22. Global Antihemophilic Factor Drug Market: Adult (2020-2025) & (K Units)
Figure 23. Antihemophilic Factor Drug Consumed in Pediatric
Figure 24. Global Antihemophilic Factor Drug Market: Pediatric (2020-2025) & (K Units)
Figure 25. Global Antihemophilic Factor Drug Sale Market Share by Application (2024)
Figure 26. Global Antihemophilic Factor Drug Revenue Market Share by Application in 2025
Figure 27. Antihemophilic Factor Drug Sales by Company in 2025 (K Units)
Figure 28. Global Antihemophilic Factor Drug Sales Market Share by Company in 2025
Figure 29. Antihemophilic Factor Drug Revenue by Company in 2025 ($ millions)
Figure 30. Global Antihemophilic Factor Drug Revenue Market Share by Company in 2025
Figure 31. Global Antihemophilic Factor Drug Sales Market Share by Geographic Region (2020-2025)
Figure 32. Global Antihemophilic Factor Drug Revenue Market Share by Geographic Region in 2025
Figure 33. Americas Antihemophilic Factor Drug Sales 2020-2025 (K Units)
Figure 34. Americas Antihemophilic Factor Drug Revenue 2020-2025 ($ millions)
Figure 35. APAC Antihemophilic Factor Drug Sales 2020-2025 (K Units)
Figure 36. APAC Antihemophilic Factor Drug Revenue 2020-2025 ($ millions)
Figure 37. Europe Antihemophilic Factor Drug Sales 2020-2025 (K Units)
Figure 38. Europe Antihemophilic Factor Drug Revenue 2020-2025 ($ millions)
Figure 39. Middle East & Africa Antihemophilic Factor Drug Sales 2020-2025 (K Units)
Figure 40. Middle East & Africa Antihemophilic Factor Drug Revenue 2020-2025 ($ millions)
Figure 41. Americas Antihemophilic Factor Drug Sales Market Share by Country in 2025
Figure 42. Americas Antihemophilic Factor Drug Revenue Market Share by Country (2020-2025)
Figure 43. Americas Antihemophilic Factor Drug Sales Market Share by Type (2020-2025)
Figure 44. Americas Antihemophilic Factor Drug Sales Market Share by Application (2020-2025)
Figure 45. United States Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Canada Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. Mexico Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 48. Brazil Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 49. APAC Antihemophilic Factor Drug Sales Market Share by Region in 2025
Figure 50. APAC Antihemophilic Factor Drug Revenue Market Share by Region (2020-2025)
Figure 51. APAC Antihemophilic Factor Drug Sales Market Share by Type (2020-2025)
Figure 52. APAC Antihemophilic Factor Drug Sales Market Share by Application (2020-2025)
Figure 53. China Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Japan Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. South Korea Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Southeast Asia Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. India Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Australia Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. China Taiwan Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 60. Europe Antihemophilic Factor Drug Sales Market Share by Country in 2025
Figure 61. Europe Antihemophilic Factor Drug Revenue Market Share by Country (2020-2025)
Figure 62. Europe Antihemophilic Factor Drug Sales Market Share by Type (2020-2025)
Figure 63. Europe Antihemophilic Factor Drug Sales Market Share by Application (2020-2025)
Figure 64. Germany Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. France Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. UK Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Italy Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. Russia Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 69. Middle East & Africa Antihemophilic Factor Drug Sales Market Share by Country (2020-2025)
Figure 70. Middle East & Africa Antihemophilic Factor Drug Sales Market Share by Type (2020-2025)
Figure 71. Middle East & Africa Antihemophilic Factor Drug Sales Market Share by Application (2020-2025)
Figure 72. Egypt Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. South Africa Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. Israel Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Turkey Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. GCC Countries Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Antihemophilic Factor Drug in 2025
Figure 78. Manufacturing Process Analysis of Antihemophilic Factor Drug
Figure 79. Industry Chain Structure of Antihemophilic Factor Drug
Figure 80. Channels of Distribution
Figure 81. Global Antihemophilic Factor Drug Sales Market Forecast by Region (2026-2031)
Figure 82. Global Antihemophilic Factor Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 83. Global Antihemophilic Factor Drug Sales Market Share Forecast by Type (2026-2031)
Figure 84. Global Antihemophilic Factor Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 85. Global Antihemophilic Factor Drug Sales Market Share Forecast by Application (2026-2031)
Figure 86. Global Antihemophilic Factor Drug Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Antihemophilic Factor Drug
Figure 2. Antihemophilic Factor Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Antihemophilic Factor Drug Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Antihemophilic Factor Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Antihemophilic Factor Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Antihemophilic Factor Drug Sales Market Share by Country/Region (2024)
Figure 10. Antihemophilic Factor Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of 250 IU
Figure 12. Product Picture of 500 IU
Figure 13. Product Picture of 1000 IU
Figure 14. Product Picture of 1500 IU
Figure 15. Product Picture of 2000 IU
Figure 16. Product Picture of 3000 IU
Figure 17. Product Picture of 4000 IU
Figure 18. Product Picture of Other potencies
Figure 19. Global Antihemophilic Factor Drug Sales Market Share by Type in 2025
Figure 20. Global Antihemophilic Factor Drug Revenue Market Share by Type (2020-2025)
Figure 21. Antihemophilic Factor Drug Consumed in Adult
Figure 22. Global Antihemophilic Factor Drug Market: Adult (2020-2025) & (K Units)
Figure 23. Antihemophilic Factor Drug Consumed in Pediatric
Figure 24. Global Antihemophilic Factor Drug Market: Pediatric (2020-2025) & (K Units)
Figure 25. Global Antihemophilic Factor Drug Sale Market Share by Application (2024)
Figure 26. Global Antihemophilic Factor Drug Revenue Market Share by Application in 2025
Figure 27. Antihemophilic Factor Drug Sales by Company in 2025 (K Units)
Figure 28. Global Antihemophilic Factor Drug Sales Market Share by Company in 2025
Figure 29. Antihemophilic Factor Drug Revenue by Company in 2025 ($ millions)
Figure 30. Global Antihemophilic Factor Drug Revenue Market Share by Company in 2025
Figure 31. Global Antihemophilic Factor Drug Sales Market Share by Geographic Region (2020-2025)
Figure 32. Global Antihemophilic Factor Drug Revenue Market Share by Geographic Region in 2025
Figure 33. Americas Antihemophilic Factor Drug Sales 2020-2025 (K Units)
Figure 34. Americas Antihemophilic Factor Drug Revenue 2020-2025 ($ millions)
Figure 35. APAC Antihemophilic Factor Drug Sales 2020-2025 (K Units)
Figure 36. APAC Antihemophilic Factor Drug Revenue 2020-2025 ($ millions)
Figure 37. Europe Antihemophilic Factor Drug Sales 2020-2025 (K Units)
Figure 38. Europe Antihemophilic Factor Drug Revenue 2020-2025 ($ millions)
Figure 39. Middle East & Africa Antihemophilic Factor Drug Sales 2020-2025 (K Units)
Figure 40. Middle East & Africa Antihemophilic Factor Drug Revenue 2020-2025 ($ millions)
Figure 41. Americas Antihemophilic Factor Drug Sales Market Share by Country in 2025
Figure 42. Americas Antihemophilic Factor Drug Revenue Market Share by Country (2020-2025)
Figure 43. Americas Antihemophilic Factor Drug Sales Market Share by Type (2020-2025)
Figure 44. Americas Antihemophilic Factor Drug Sales Market Share by Application (2020-2025)
Figure 45. United States Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Canada Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. Mexico Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 48. Brazil Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 49. APAC Antihemophilic Factor Drug Sales Market Share by Region in 2025
Figure 50. APAC Antihemophilic Factor Drug Revenue Market Share by Region (2020-2025)
Figure 51. APAC Antihemophilic Factor Drug Sales Market Share by Type (2020-2025)
Figure 52. APAC Antihemophilic Factor Drug Sales Market Share by Application (2020-2025)
Figure 53. China Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Japan Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. South Korea Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Southeast Asia Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. India Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Australia Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. China Taiwan Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 60. Europe Antihemophilic Factor Drug Sales Market Share by Country in 2025
Figure 61. Europe Antihemophilic Factor Drug Revenue Market Share by Country (2020-2025)
Figure 62. Europe Antihemophilic Factor Drug Sales Market Share by Type (2020-2025)
Figure 63. Europe Antihemophilic Factor Drug Sales Market Share by Application (2020-2025)
Figure 64. Germany Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. France Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. UK Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Italy Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. Russia Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 69. Middle East & Africa Antihemophilic Factor Drug Sales Market Share by Country (2020-2025)
Figure 70. Middle East & Africa Antihemophilic Factor Drug Sales Market Share by Type (2020-2025)
Figure 71. Middle East & Africa Antihemophilic Factor Drug Sales Market Share by Application (2020-2025)
Figure 72. Egypt Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. South Africa Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. Israel Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Turkey Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. GCC Countries Antihemophilic Factor Drug Revenue Growth 2020-2025 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Antihemophilic Factor Drug in 2025
Figure 78. Manufacturing Process Analysis of Antihemophilic Factor Drug
Figure 79. Industry Chain Structure of Antihemophilic Factor Drug
Figure 80. Channels of Distribution
Figure 81. Global Antihemophilic Factor Drug Sales Market Forecast by Region (2026-2031)
Figure 82. Global Antihemophilic Factor Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 83. Global Antihemophilic Factor Drug Sales Market Share Forecast by Type (2026-2031)
Figure 84. Global Antihemophilic Factor Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 85. Global Antihemophilic Factor Drug Sales Market Share Forecast by Application (2026-2031)
Figure 86. Global Antihemophilic Factor Drug Revenue Market Share Forecast by Application (2026-2031)
